Treatments for disease damage in cutaneous lupus erythematosus: A narrative review.
alopecia
cutaneous lupus erythematosus
disease damage
dyspigmentation
scarring
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
18
02
2021
accepted:
17
06
2021
pubmed:
22
6
2021
medline:
3
11
2021
entrez:
21
6
2021
Statut:
ppublish
Résumé
Cutaneous lupus erythematosus (CLE) is an autoimmune photosensitive disorder that affects the skin. CLE lesions can have signs of skin damage including dyspigmentation, scarring, atrophy and/or alopecia. Disease damage secondary to CLE can be cosmetically disfiguring and causes patients significant distress. While many current treatments for CLE focus primarily on reducing inflammation, there are few options for managing disease damage. Providers currently lack strong guidance on managing CLE damage due to the paucity of literature on this topic. Because of this knowledge gap, we aim to provide an overview of what is currently known about the pathogenesis and management of signs of disease damage in CLE. In this narrative review, Pubmed, Ovid Medline, and Google scholar were searched for relevant articles assessing pathogenesis and treatment of disease damage. Therapeutic options for CLE damage, including hyperpigmentation (laser and camouflage), hypopigmentation (melanocyte grafting and camouflage), scarring (laser, dermabrasion, and camouflage), atrophy (filler, fat transplantation, and flap procedures), and scarring alopecia (hair transplantation and camouflage) were identified. We found that investigations of therapeutics for CLE disease damage primarily consist of case reports and small case series. Reported adverse events due to treatment for CLE disease damage range from temporary erythema and discomfort to disease reactivation and pigmentary defects. There are various treatments for disease damage for each sign of disease damage. However, more robust investigations are needed to assess disease pathogenesis and improve treatments of disease damage due to CLE.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15034Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Creadore A, Watchmaker J, Maymone MBC, Pappas L, Vashi NA, Lam C. Cosmetic treatment in patients with autoimmune connective tissue diseases: Best practices for patients with lupus erythematosus. J Am Acad Dermatol. 2020;83(2):343-363.
Verma SM, Okawa J, Propert KJ, Werth VP. The impact of skin damage due to cutaneous lupus on quality of life. Br J Dermatol. 2014;170(2):315-321.
Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20-31.
Haber JS, Merola JF, Werth VP. Classifying discoid lupus erythematosus: background, gaps, and difficulties. Int J Womens Dermatol. 2017;3(1 Suppl):S62-S66.
Fu C, Chen J, Lu J, et al. Roles of inflammation factors in melanogenesis (Review). Mol Med Rep. 2020;21(3):1421-1430.
Sofen B, Prado G, Emer J. Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion. Skin Therapy Lett. 2016;21(1):1-7.
Byun YS, Son JH, Cho YS, et al. Intense Pulsed Light and Q-Switched 1,064-nm Neodymium-Doped Yttrium Aluminum Garnet Laser Treatment for the Scarring Lesion of Discoid Lupus Erythematosus. Ann Dermatol. 2017;29(3):331-333.
Agbai O, Hamzavi I, Jagdeo J. Laser treatments for postinflammatory hyperpigmentation: a systematic review. JAMA Dermatol. 2017;153(2):199-206.
Shah S, Alster TS. Laser treatment of dark skin: an updated review. Am J Clin Dermatol. 2010;11(6):389-397.
Wolfe JT, Weinberg JM, Elenitsas R, Uberti-Benz M. Cutaneous lupus erythematosus following laser-induced thermal injury. Arch Dermatol. 1997;133(3):392-393.
Vachiramon V, Thadanipon K. Postinflammatory hypopigmentation. Clin Exp Dermatol. 2011;36(7):708-714.
Franca AF, de Souza EM. Histopathology and immunohistochemistry of depigmented lesions in lupus erythematosus. J Cutan Pathol. 2010;37(5):559-564.
Ruiz-Maldonado R, Orozco-Covarrubias ML. Postinflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg. 1997;16(1):36-43.
Mulekar SV, Ghwish B, Al Issa A, Al EA. Melanocyte-keratinocyte transplantation for postdiscoid lupus erythematosus depigmentation. Dermatol Surg. 2008;34(2):261-262.
Gupta S. Epidermal grafting for depigmentation due to discoid lupus erythematosus. Dermatology. 2001;202(4):320-323.
Falabella R. Repigmentation of stable leukoderma by autologous minigrafting. J Dermatol Surg Oncol. 1986;12(2):172-179.
Lobuono P, Shatin H. Transplantation of hair bulbs and melanocytes into leukodermic scars. J Dermatol Surg. 1976;2(1):53-55.
Al-Refu K, Goodfield M. Scar classification in cutaneous lupus erythematosus: morphological description. Br J Dermatol. 2009;161(5):1052-1058.
Sole C, Gimenez-Barcons M, Ferrer B, Ordi-Ros J, Cortes-Hernandez J. Microarray study reveals a transforming growth factor-beta-dependent mechanism of fibrosis in discoid lupus erythematosus. Br J Dermatol. 2016;175(2):302-313.
Liu Y, Li Y, Li N, et al. TGF-beta1 promotes scar fibroblasts proliferation and transdifferentiation via up-regulating MicroRNA-21. Sci Rep. 2016;6:32231.
Achtman JC, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Arthritis Res Ther. 2015;17:182.
Wenzel J, Uerlich M, Worrenkamper E, Freutel S, Bieber T, Tuting T. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol. 2005;153(5):1011-1015.
Jarvinen TM, Kanninen P, Jeskanen L, et al. Matrix metalloproteinases as mediators of tissue injury in different forms of cutaneous lupus erythematosus. Br J Dermatol. 2007;157(5):970-980.
Ekback MP, Troilius A. Laser therapy for refractory discoid lupus erythematosus when everything else has failed. J Cosmet Laser Ther. 2013;15(5):260-265.
Tremblay JF, Carey W. Atrophic facial scars secondary to discoid lupus erythematous: treatment using the Erbium:YAG laser. Dermatol Surg. 2001;27(7):675-677.
Walker SL, Harland CC. Carbon dioxide laser resurfacing of facial scarring secondary to chronic discoid lupus erythematosus. Br J Dermatol. 2000;143(5):1101-1102.
Henderson DL, Odom JC. Laser treatment of discoid lupus (case report). Lasers Surg Med. 1986;6(1):12-15.
Yumeen S, Khan T. Laser Erbium-Yag Resurfacing. Treasure Island, FL: StatPearls Publishing; 2021. https://www.ncbi.nlm.nih.gov/books/NBK560931/.
Ramsdell WM. Fractional carbon dioxide laser resurfacing. Semin Plast Surg. 2012;26(3):125-130.
Baniandres O, Boixeda P, Belmar P, Perez A. Treatment of lupus erythematosus with pulsed dye laser. Lasers Surg Med. 2003;32(4):327-330.
Ratner D, Skouge JW. Discoid lupus erythematosus scarring and dermabrasion: a case report and discussion. J Am Acad Dermatol. 1990;22(2 Pt 1):314-316.
Wang RF, Maher M, Chung C, Kaffenberger JA. Koebner phenomenon of discoid lupus erythematosus on old tattoos. Lupus. 2019;28(2):241-243.
Braunstein I, Werth VP. Update on management of connective tissue panniculitides. Dermatol Ther. 2012;25(2):173-182.
Abigail Fogo SBM. Facial lipoatrophy secondary to lupus profundus: Treatment with large particle hyaluronic acid. J Am Acad Dermatol. 2011;64(2):AB165.
Eastham AB, Liang CA, Femia AN, Lee TC, Vleugels RA, Merola JF. Lupus erythematosus panniculitis-induced facial atrophy: effective treatment with poly-L-lactic acid and hyaluronic acid dermal fillers. J Am Acad Dermatol. 2013;69(5):e260-e262.
Carvalho Costa IM, Salaro CP, Costa MC. Polymethylmethacrylate facial implant: a successful personal experience in Brazil for more than 9 years. Dermatol Surg. 2009;35(8):1221-1227.
Gupta K, Bhari N, Verma KK, Gupta S. Permanent Injectable Polyacrylamide Hydrogel Dermal Filler for a Large Subcutaneous Defect Secondary to Lupus Panniculitis. Dermatol Surg. 2017;43(1):152-154.
Wong ITY, Hanna E, Pon K. Poly-L-lactic acid for treating facial lipoatrophy secondary to lupus erythematosus panniculitis. Dermatol Surg. 2020;47:848.
Fogo AB. Saqib. Facial lipoatrophy secondary to lupus profundus: Treatment with large particle hyaluronic acid. J Am Acad Dermatol. 2011;64(2):AB165.
Yoon J, Kim HM, Kim TH, Kim CW, Sun YW, Yoon TJ. Autologous fat transfer in a patient with lupus erythematosus profundus. Case Rep Dermatol. 2012;4(3):207-210.
Gleeson CM, Lucas S, Langrish CJ, Barlow RJ. Acute fatal fat tissue embolism after autologous fat transfer in a patient with lupus profundus. Dermatol Surg. 2011;37(1):111-115.
Valdatta L, Cherubino M, Tamborini F, Pellegatta I, Maggiulli F. A case of facial lipoatrophy secondary to lupus profundus managed with lipofilling technique. Case Rep Dermatol Med. 2012;2012:720518.
Polivka L, Revol M, Battistella M, Bachelez H. Lipofilling: A new therapeutic option for the treatment of lupus panniculitis-induced atrophy. Case Rep Dermatol. 2016;8(3):323-326.
Yesilada AK, Sevim KZ, Sirvan SS, Irmak F, Tatlidede HS. Severe symmetrical facial lipoatrophy in a patient with discoid lupus erythematosus. J Craniofac Surg. 2012;23(5):e461-e463.
Yoshimura K, Sato K, Aoi N, et al. Cell-assisted lipotransfer for facial lipoatrophy: efficacy of clinical use of adipose-derived stem cells. Dermatol Surg. 2008;34(9):1178-1185.
Lewandowicz E, Zielinski T, Iljin A, Fijalkowska M, Kasielska-Trojan A, Antoszewski B. Surgical treatment of skin lesions in lupus erythematosus. Postepy Dermatol Alergol. 2014;31(6):405-409.
Pinski KS, Roenigk HH Jr. Autologous fat transplantation. Long-term follow-up. J Dermatol Surg Oncol. 1992;18(3):179-184.
Kadam D, Pillai V, Bhandary S, Hukkeri RY, Kadam M. Facial contour deformity correction with microvascular flaps based on the 3-dimentional template and facial moulage. Indian J Plast Surg. 2013;46(3):521-528.
Concha JSS, Werth VP. Alopecias in lupus erythematosus. Lupus Sci Med. 2018;5(1):e000291.
Nordström RE. Hair transplantation. The use of hairbearing compound grafts for correction of alopecia due to chronic discoid lupus erythematosus, traumatic alopecia, and male pattern baldness. Scand J Plast Reconstr Surg Suppl. 1976;14:1-37.